Reply

Abstract

1.84%, P < 0.01; and versus 1.69%, P < 0.01). (4) In another study, the poor anticoagulation control group had a significantly higher cumulative risk of major adverse cardiovascular events than the moderate and good anticoagulation control groups (P < 0.001, by log-rank test). (5) More notably, the quality of anticoagulation is poor in about one-third of the general population with atrial fibrillation. (4,5) If patients had a concomitant diagnosis of liver cirrhosis and a risk of variceal bleeding, the proportion of those with poor anticoagulation control would be increased.Additionally, as shown in Cerini et al.'s Tables 3 and 4, (1) the subgroup analysis of patients treated with anticoagulation for cardiovascular diseases demonstrated that anticoagulation significantly increased the 6-week mortality. (1) Thus, the quality of anticoagulation, which is evaluated according to the time in the therapeutic range, should be taken into account to clarify how anticoagulation impacts the outcomes of UGIB in liver cirrhosis.